# Filing Detail

Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-24-012070
Filing Date
2024-03-29
Accepted
2024-03-29 21:29:19
Documents
3
Period of Report
2024-03-25

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | ownership.html | 4 |
1 |  | ownership.xml | 4 | 3911
2 |  | ex24.htm | EX-24 | 1125
3 |  | ex24_001.jpg | GRAPHIC | 1093602
| Complete submission text file | 0001493152-24-012070.txt |  | 1512598

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Issuer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address
Barrage Khalil (Reporting) CIK: 0001666011 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-12555 | Film No.: 24805277